The stock of Asterias Biotherapeutics Inc (NYSEMKT:AST) hit a new 52-week high and has $8.55 target or 54.00% above today’s $5.55 share price. The 8 months bullish chart indicates low risk for the $319.13 million company. The 1-year high was reported on Nov, 18 by Barchart.com. If the $8.55 price target is reached, the company will be worth $172.33 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 101,268 shares traded hands. Asterias Biotherapeutics Inc (NYSEMKT:AST) has risen 28.84% since April 18, 2016 and is uptrending. It has outperformed by 24.41% the S&P500.
Asterias Biotherapeutics Inc (NYSEMKT:AST) Ratings Coverage
Out of 3 analysts covering Asterias Biotherapeutics (NYSEMKT:AST), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $10 is the highest target while $5.50 is the lowest. The $8.17 average target is 47.21% above today’s ($5.55) stock price. Asterias Biotherapeutics has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The company was initiated on Monday, May 23 by Chardan Capital Markets. As per Thursday, September 3, the company rating was upgraded by Zacks. MLV maintained Asterias Biotherapeutics Inc (NYSEMKT:AST) on Tuesday, August 11 with “Buy” rating. FBR Capital initiated the stock with “Outperform” rating in Thursday, November 19 report.
According to Zacks Investment Research, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California.”
More important recent Asterias Biotherapeutics Inc (NYSEMKT:AST) news were published by: Finance.Yahoo.com which released: “Ryan Chavez Appointed Chief Financial Officer of Asterias Biotherapeutics” on November 17, 2016, also Prnewswire.com published article titled: “Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury …”, Prnewswire.com published: “Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with …” on September 14, 2016. More interesting news about Asterias Biotherapeutics Inc (NYSEMKT:AST) was released by: Prnewswire.com and their article: “Asterias Biotherapeutics Announces Record Date for Distribution of Warrants to …” with publication date: March 31, 2016.
AST Company Profile
Asterias Biotherapeutics, Inc., incorporated on October 24, 2012, is a biotechnology company. The Firm is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Firm has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. The Firm is focused on developing therapies to treat conditions with medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with its collaboration partner, Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells which could provide off the shelf cells that teaches a patient’s immune system to recognize and fight cancer cells, in non-small cell lung cancer. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells, in an initial clinical indication of spinal cord injury, with potential for later expansion into other neurodegenerative diseases, such as stroke and multiple sclerosis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.